Ali Tehrani, CEO and President of Zymeworks: Lucky to Provide Only Non-Exclusive Licenses

TL;DR

Xym Works has established partnerships with major pharmaceutical companies to license their tools for building therapeutics, while also focusing on their own pipeline development.

Transcript

the investing news network I'm Gabriel Costa here at the food merchants health care investor conference in Toronto today I'm speaking with Ally from Simon works he was the president and CEO of the company and Neal Columbus the chief financial officer also thank you for both of your time today thank you it's our pleasure now as I works have had a lo... Read More

Key Insights

• ❓ Xym Works is an innovative company focused on multifunctional biologics.
• 🔨 They have established partnerships with major pharmaceutical companies, offering non-exclusive licenses to their tools.
• 😤 The majority of their team is dedicated to their own clinical pipeline development.
• 🚀 Xym Works has upcoming milestones including a presentation at the ASCO conference and the launch of their CW 49 program.

Questions & Answers

Q: How have partnerships affected Xym Works' company?

The partnerships with major pharmaceutical companies have generated interest in their tools and platforms, leading to non-exclusive licensing deals. This allows Xym Works to do more deals and develop their own therapeutics while diversifying their partnerships.

Q: How is Xym Works balancing partnerships and their own pipeline development?

While it may appear that they are focusing more on licensing deals, the reality is that the majority of their team is working on their own clinical pipeline. Partnerships do not take away bandwidth from their pipeline development and the money received goes into generating next-generation biologics.

Q: What milestones can investors look forward to from Xym Works?

Xym Works is excited about their upcoming presentation at the ASCO conference where their lead program for breast and gastric cancer will be showcased. They are also excited about their next program, CW 49, going into the clinic and the potential for more partners to take programs into the clinic.

Q: How does Xym Works' therapeutic program for her2 differ from other companies?

Xym Works is one of only two companies, along with Daichi, selected for an oral presentation at an upcoming conference. Being part of the lead group in a competitive field demonstrates the demand for their program. They are focused on finding ways to send cancer patients back home and differentiate their therapy through robust data.

Summary & Key Takeaways

• Xym Works is an innovative company focused on the research and development of multifunctional biologics, with a deep pipeline and tools for protein engineering.

• They have established six partnerships with pharma companies like Merck, GSK, and Eli Lilly, providing non-exclusive licenses to their tools.

• While it may seem like they are doing more licensing than focusing on their own pipeline, the majority of their team is actually dedicated to their own clinical programs.